Hassen M, Mousa N, Radwan S, Gabre R
Inflammation. 2025; .
PMID: 40064794
DOI: 10.1007/s10753-024-02187-z.
Brandao S, Lazzari E, Vitorino R, Meroni G, Reis-Mendes A, Neuparth M
Arch Toxicol. 2025; .
PMID: 40035845
DOI: 10.1007/s00204-025-04006-2.
Boncimino F, DAuria L, Todorova K, van der Zanden S, Neefjes J, Mandinova A
Cell Death Discov. 2025; 11(1):24.
PMID: 39863572
PMC: 11762975.
DOI: 10.1038/s41420-025-02307-0.
Caballero-Valderrama M, Bevilacqua E, Echevarria M, Salvador-Bofill F, Ordonez A, Lopez-Haldon J
Biomedicines. 2025; 13(1).
PMID: 39857629
PMC: 11762338.
DOI: 10.3390/biomedicines13010045.
Garcia K, Theismann J, Schneider T, LeComte R, Jarmolowicz D, Johnson M
Naunyn Schmiedebergs Arch Pharmacol. 2025; .
PMID: 39820646
DOI: 10.1007/s00210-024-03766-5.
Doxorubicin or Epirubicin Versus Liposomal Doxorubicin Therapy-Differences in Cardiotoxicity.
Buchalska B, Kaminska K, Kowara M, Sobiborowicz-Sadowska A, Cudnoch-Jedrzejewska A
Cardiovasc Toxicol. 2025; 25(2):248-268.
PMID: 39810066
DOI: 10.1007/s12012-024-09952-4.
Improved Therapeutic Efficacy of Doxorubicin Chemotherapy With Cannabidiol in 4T1 Mice Breast Cancer Model.
Tabatabaei K, Moazzezi S, Emamgholizadeh M, Vaez H, Baradaran B, Shokouhi B
Cancer Med. 2024; 13(21):e70395.
PMID: 39503169
PMC: 11538943.
DOI: 10.1002/cam4.70395.
The mechanism and therapeutic strategies in doxorubicin-induced cardiotoxicity: Role of programmed cell death.
Li Y, Yan J, Yang P
Cell Stress Chaperones. 2024; 29(5):666-680.
PMID: 39343295
PMC: 11490929.
DOI: 10.1016/j.cstres.2024.09.001.
MicroRNA-146: Biomarker and Mediator of Cardiovascular Disease.
Mahdavi F, Mardi S, Mohammadi S, Ansari S, Yaslianifard S, Fallah P
Dis Markers. 2024; 2022:7767598.
PMID: 39281713
PMC: 11401689.
DOI: 10.1155/2022/7767598.
Potential role of endoplasmic reticulum stress in doxorubicin-induced cardiotoxicity-an update.
Sun M, Zhang X, Tan B, Zhang Q, Zhao X, Dong D
Front Pharmacol. 2024; 15:1415108.
PMID: 39188945
PMC: 11345228.
DOI: 10.3389/fphar.2024.1415108.
Inflammatory Reprogramming Mediates Changes in Three-Dimensional Strain Capacity and Cardiac Function in Beagle Dogs with Doxorubicin-Related Cardiomyopathy.
Chen Y, Shen Y, Zhang H, Wang X, Xu Y, Zhang J
Rev Cardiovasc Med. 2024; 25(2):62.
PMID: 39077361
PMC: 11263182.
DOI: 10.31083/j.rcm2502062.
Recent Advances in the Mechanisms of Cell Death and Dysfunction in Doxorubicin Cardiotoxicity.
Wang T, Ma Y, Gao S, Zhang W, Han D, Cao F
Rev Cardiovasc Med. 2024; 24(11):336.
PMID: 39076437
PMC: 11272847.
DOI: 10.31083/j.rcm2411336.
Statins for the Primary Prevention of Anthracycline Cardiotoxicity: A Comprehensive Review.
Bhasin V, Vakilpour A, Scherrer-Crosbie M
Curr Oncol Rep. 2024; 26(10):1197-1204.
PMID: 39002055
PMC: 11480194.
DOI: 10.1007/s11912-024-01579-6.
Sodium-glucose cotransporter 2 inhibitors and the cancer patient: from diabetes to cardioprotection and beyond.
Camilli M, Viscovo M, Maggio L, Bonanni A, Torre I, Pellegrino C
Basic Res Cardiol. 2024; 120(1):241-262.
PMID: 38935171
PMC: 11790819.
DOI: 10.1007/s00395-024-01059-9.
Red ginseng prevents doxorubicin-induced cardiomyopathy by inhibiting cell death via activating the Nrf2 pathway.
Yoshikawa N, Hirata N, Kurone Y, Shimoeda S
Cardiooncology. 2024; 10(1):39.
PMID: 38909271
PMC: 11193215.
DOI: 10.1186/s40959-024-00242-0.
Liraglutide Pretreatment Does Not Improve Acute Doxorubicin-Induced Cardiotoxicity in Rats.
Tonon C, Monte M, Balin P, Fujimori A, Ribeiro A, Ferreira N
Int J Mol Sci. 2024; 25(11).
PMID: 38892020
PMC: 11172760.
DOI: 10.3390/ijms25115833.
Protective effects of Panax ginseng as a medical food against chemical toxic agents: molecular and cellular mechanisms.
Rameshrad M, Naraki K, Memariani Z, Hosseinzadeh H
Naunyn Schmiedebergs Arch Pharmacol. 2024; 397(11):8395-8419.
PMID: 38861010
DOI: 10.1007/s00210-024-03186-5.
Anthracycline-Induced Cardiomyopathy in Cancer Survivors: Management and Long-Term Implications.
Mohsenizadeh S, Rajaeinejad M, Khoshfetrat M, Arefizadeh R, Mousavi S, Mosaed R
Adv Exp Med Biol. 2024; 1474():179-199.
PMID: 38842787
DOI: 10.1007/5584_2024_804.
Directly targeting BAX for drug discovery: Therapeutic opportunities and challenges.
Zhang Z, Hou L, Liu D, Luan S, Huang M, Zhao L
Acta Pharm Sin B. 2024; 14(6):2378-2401.
PMID: 38828138
PMC: 11143528.
DOI: 10.1016/j.apsb.2024.02.010.
Metabolomic signatures of carfilzomib-related cardiotoxicity in patients with multiple myeloma.
Shabnaz S, Nguyen T, Williams R, Rubinstein S, Garrett T, Tantawy M
Clin Transl Sci. 2024; 17(5):e13828.
PMID: 38783568
PMC: 11116757.
DOI: 10.1111/cts.13828.